Comment
doi: 10.1016/S0140-6736(23)00336-7.
Key questions regarding the SYMPLICITY HTN-3 trial
Affiliations
- PMID: 37087165
- DOI: 10.1016/S0140-6736(23)00336-7
Item in Clipboard
Comment
Key questions regarding the SYMPLICITY HTN-3 trial
Lancet.
.
No abstract available
Comment in
-
Key questions regarding the SYMPLICITY HTN-3 trial - Authors' reply.Lancet. 2023 Apr 22;401(10385):1337-1338. doi: 10.1016/S0140-6736(23)00337-9. Lancet. 2023. PMID: 37087166 No abstract available.
Comment on
-
Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.Lancet. 2022 Oct 22;400(10361):1405-1416. doi: 10.1016/S0140-6736(22)01787-1. Epub 2022 Sep 18. Lancet. 2022. PMID: 36130612 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
